SCTX
Scribe Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.67
−6.95%Latest reported
- Last report date
- Sep 2, 2026
- EPS actual
- -$2.62
- EPS estimate
- -$3.62
- Revenue actual
- $1.9M
- Revenue estimate
- $3.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +27.6%
- Revenue beats (12Q)
- 0
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $49
- PT range
- $37 – $60
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 2, 2026